 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Phase I/II Recurrent Malignant Gliomas Trial - United States In July 2006, the Company commenced enrolment in a Phase I/II recurrent malignant gliomas study. The primary objective of the study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and safety profile of REOLYSIN®. Secondary objectives include the evaluation of viral replication, immune response to the virus and any evidence of antitumour activity. Patients with recurrent malignant gliomas will be treated with REOLYSIN® through infusion delivery. An additional group of patients will be treated at the maximum tolerated dose ("MTD"). See related press releases: July 11, 2006 - Oncolytics Biotech Inc. Begins Patient Enrolment in U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial February 28, 2005 - Oncolytics Biotech Receives FDA Clearance to Initiate Phase I/II Recurrent Malignant Gliomas Clinical Trial |
|
|||||||||||
 |
|
 |